13 May 2021 ORYZON to present new clinical data and corporate updates at international conferences in May and June
6 April 2021 ORYZON starts preclinical collaboration on autism with the Seaver Autism Center at Mount Sinai
29 March 2021 ORYZON enrolls first patient in PORTICO, a Phase IIb clinical trial with vafidemstat in Borderline Personality Disorder
24 March 2021 ORYZON publishes vafidemstat first-in-human clinical trial manuscript in CNS Drugs journal
15 March 2021 ORYZON announces successful pre-IND meeting with FDA for the clinical development of vafidemstat in Borderline Personality Disorder
9 March 2021 ORYZON presents vafidemstat 12-month clinical data from its Phase IIa clinical trials ETHERAL and REIMAGINE-AD in Alzheimer’s at the virtual AD/PD-2021 conference
22 February 2021 ORYZON reports results and corporate update for 4th quarter and year ended December 31, 2020